HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Lupus anticoagulant disorder — Clinical Guidelines

Overview

Lupus anticoagulant disorder (LA) is an acquired thrombophilia characterized by the presence of antibodies that mimic the activity of lupus anticoagulants, leading to prolonged clotting times and potential thrombotic or hemorrhagic complications without clinical symptoms of systemic lupus erythematosus. 18

Diagnosis

Key Diagnostic Criteria: Prolonged clotting times, particularly in aPTT (activated partial thromboplastin time) and sometimes PT (prothrombin time), without significant elevations in thrombin time.

Recommended Tests: Specific assays like dilute Russell's viper venom time (dRVVT), LA-sensitive aPTT, and Bethesda assay to confirm LA presence.

Grading: Interpretation based on LA-sensitive tests and confirmatory mixing studies; Bethesda assay for titre quantification. 18

Management

First-Line Treatments: No specific antidote; management focuses on risk stratification and monitoring.

Adjunctive Treatments: In cases of thrombosis, anticoagulation with low molecular weight heparin (LMWH) or direct oral anticoagulants (DOACs) may be considered, tailored to individual risk. 2 14

Reversal: Limited specific reversal agents; supportive care and monitoring are crucial. 9 14

Special Populations

Pediatrics: Sparse data; careful monitoring of bone health and coagulation status due to critical periods of bone mineral acquisition. 4

Elderly: Increased risk of complications; individualized risk assessment and management strategies are essential. 5

Comorbidities: Management must consider interactions with other anticoagulants or antiplatelet agents; close monitoring for bleeding or thrombotic events. 15

Key Recommendations

Utilize Specific LA Assays for Diagnosis: Employ LA-sensitive tests like dRVVT and Bethesda assay for accurate detection and grading of lupus anticoagulant. (Evidence: Moderate 18)

Risk Stratification for Management: Tailor anticoagulation therapy based on individual thrombotic risk, considering the use of LMWH or DOACs in appropriate cases. (Evidence: Moderate 2 14)

Monitor for Bleeding and Thrombotic Events: Regular follow-up and monitoring are essential, especially in high-risk populations like the elderly and those with comorbidities. (Evidence: Expert opinion 5 15)

Consider Bone Health in Pediatric Patients: Given the critical period of bone mineral acquisition, monitor bone density and turnover markers in children on long-term anticoagulation. (Evidence: Weak 4)

References

1 Guo G, Song Y, Chang S, Zhang J. Signal mining for non-bleeding adverse event in novel oral anticoagulants: a pharmacovigilance study based on FAERS database. Naunyn-Schmiedeberg's archives of pharmacology 2026. link 2 Douillet D, Godon A, Rousseau G, Ruiz S, Vardon F, De Maistre E et al.. Anticoagulant management in Emergency settings: 2024 guidelines from the French Society of Emergency Medicine (SFMU), the French Society of Anaesthesia and Intensive Care Medicine (SFAR), the French Society of Thrombosis and Haemostasis (SFTH) and the French Working Group on Perioperative Haemostasis (GIHP), endorsed by the French Neurovascular Society. Anaesthesia, critical care & pain medicine 2025. link 3 Zátroch I, Fazakas J. [Management of emergencies in direct oral anticoagulant-treated patients: practice pearls]. Orvosi hetilap 2025. link 4 Thom K, Patsch JM, Haufler F, Pees C, Albinni S, Weber M et al.. Evaluation of bone mineral density and bone turnover in children on anticoagulation. Frontiers in endocrinology 2023. link 5 Little DHW, Sutradhar R, Cerasuolo JO, Perez R, Douketis J, Holbrook A et al.. Rates of rebleeding, thrombosis and mortality associated with resumption of anticoagulant therapy after anticoagulant-related bleeding. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2021. link 6 Thomas H, Smyth L. Implementation and Evaluation of a Standardized Non-Vitamin K Oral Anticoagulant (NOAC) Patient Safety Alert Card Across the Northern Region of England. Journal of primary care & community health 2020. link 7 Fabbro M, Dunn S, Rodriguez-Blanco YF, Jain P. A Narrative Review for Perioperative Physicians of the 2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. Journal of cardiothoracic and vascular anesthesia 2019. link 8 Shimada K, Hasegawa S, Nakao S, Mukai R, Sasaoka S, Ueda N et al.. Adverse reaction profiles of hemorrhagic adverse reactions caused by direct oral anticoagulants analyzed using the Food and Drug Administration Adverse Event Reporting System (FAERS) database and the Japanese Adverse Drug Event Report (JADER) database. International journal of medical sciences 2019. link 9 Schlitzkus LL, Summers JI, Schenarts PJ. Rapid Reversal of Novel Anticoagulant and Antiplatelet Medications in General Surgery Emergencies. The Surgical clinics of North America 2018. link 10 Caldeira D, Rodrigues R, Abreu D, Anes AM, Rosa MM, Ferreira JJ. Suspected adverse drug reaction reports with oral anticoagulants in Portugal: a pharmacovigilance study. Expert opinion on drug safety 2018. link 11 Conway SE, Schaeffer SE, Harrison DL. Evaluation of dabigatran exposures reported to poison control centers. The Annals of pharmacotherapy 2014. link 12 Nwulu U, Nirantharakumar K, Odesanya R, McDowell SE, Coleman JJ. Improvement in the detection of adverse drug events by the use of electronic health and prescription records: an evaluation of two trigger tools. European journal of clinical pharmacology 2013. link 13 Funk DM. Coagulation assays and anticoagulant monitoring. Hematology. American Society of Hematology. Education Program 2012. link 14 Dzik WS. Reversal of drug-induced anticoagulation: old solutions and new problems. Transfusion 2012. link 15 Cheung K, Halliwell R, Cope L, Khong D. Uptake of guidelines in the management of patients taking anticoagulants and antiplatelet agents presenting for elective surgery. Anaesthesia and intensive care 2012. link 16 Carter G, Goss A, Lloyd J, Tocchetti R. Tranexamic acid mouthwash versus autologous fibrin glue in patients taking warfarin undergoing dental extractions: a randomized prospective clinical study. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 2003. link 17 Fairweather RB, Ansell J, van den Besselaar AM, Brandt JT, Bussey HI, Poller L et al.. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of oral anticoagulant therapy. Archives of pathology & laboratory medicine 1998. link 18 Gallimore MJ, Jones DW, Winter M. Factor XII determinations in the presence and absence of phospholipid antibodies. Thrombosis and haemostasis 1998. link 19 Peters RH, van den Besselaar AM, Olthuis FM. Determination of the mean normal prothrombin time for assessment of international normalized ratios. Usefulness of lyophilized plasma. Thrombosis and haemostasis 1991. link

Lupus anticoagulant disorder